Eosinophilic esophagitis

A clinicopathological review

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Eosinophilic esophagitis (EoE) is considered to be a chronic antigen-driven disease whereby food and/or aeroallergens induce a chronic inflammatory infiltrate in the esophagus, resulting in pathological hyperplasia of the epithelia and muscular layers, and fibrosis of the lamina propria (referred to collectively as remodelling) and the symptoms of dysphagia and food impaction. EoE shares features with other atopic conditions of asthma and atopic dermatitis, such as a TH2 cytokine milieu and a mixed inflammatory infiltrate of eosinophils, mast cells and lymphocytes. Relatively distinct features include the strong male predominance amongst adult patients, and the expression of the eosinophil chemokine eotaxin 3. Current first line treatments such as strict dietary modification and corticosteroids fail many patients. Looking forward, clarification of distinct genotype/phenotype associations, determining the reversibility of remodelling following treatment, and the development of new pharmacotherapies that target fibrotic pathways (as opposed to eosinophilic inflammation per se) or specifically improve barrier integrity appear relevant.

Original languageEnglish
Pages (from-to)12 - 22
Number of pages11
JournalPharmacology and Therapeutics
Volume146
DOIs
Publication statusPublished - 2015

Keywords

  • Allergy
  • Diet
  • Dysphagia
  • Eosinophil
  • Esophagitis
  • Remodelling

Cite this

@article{fc5018e7e4bd47b5af2c3b64cebe031f,
title = "Eosinophilic esophagitis: A clinicopathological review",
abstract = "Eosinophilic esophagitis (EoE) is considered to be a chronic antigen-driven disease whereby food and/or aeroallergens induce a chronic inflammatory infiltrate in the esophagus, resulting in pathological hyperplasia of the epithelia and muscular layers, and fibrosis of the lamina propria (referred to collectively as remodelling) and the symptoms of dysphagia and food impaction. EoE shares features with other atopic conditions of asthma and atopic dermatitis, such as a TH2 cytokine milieu and a mixed inflammatory infiltrate of eosinophils, mast cells and lymphocytes. Relatively distinct features include the strong male predominance amongst adult patients, and the expression of the eosinophil chemokine eotaxin 3. Current first line treatments such as strict dietary modification and corticosteroids fail many patients. Looking forward, clarification of distinct genotype/phenotype associations, determining the reversibility of remodelling following treatment, and the development of new pharmacotherapies that target fibrotic pathways (as opposed to eosinophilic inflammation per se) or specifically improve barrier integrity appear relevant.",
keywords = "Allergy, Diet, Dysphagia, Eosinophil, Esophagitis, Remodelling",
author = "Hamish Philpott and Sanjay Nandurkar and Francis Thien and Gibson, {Peter R.} and Royce, {Simon G.}",
year = "2015",
doi = "10.1016/j.pharmthera.2014.09.001",
language = "English",
volume = "146",
pages = "12 -- 22",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier",

}

Eosinophilic esophagitis : A clinicopathological review. / Philpott, Hamish; Nandurkar, Sanjay; Thien, Francis; Gibson, Peter R.; Royce, Simon G.

In: Pharmacology and Therapeutics, Vol. 146, 2015, p. 12 - 22.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Eosinophilic esophagitis

T2 - A clinicopathological review

AU - Philpott, Hamish

AU - Nandurkar, Sanjay

AU - Thien, Francis

AU - Gibson, Peter R.

AU - Royce, Simon G.

PY - 2015

Y1 - 2015

N2 - Eosinophilic esophagitis (EoE) is considered to be a chronic antigen-driven disease whereby food and/or aeroallergens induce a chronic inflammatory infiltrate in the esophagus, resulting in pathological hyperplasia of the epithelia and muscular layers, and fibrosis of the lamina propria (referred to collectively as remodelling) and the symptoms of dysphagia and food impaction. EoE shares features with other atopic conditions of asthma and atopic dermatitis, such as a TH2 cytokine milieu and a mixed inflammatory infiltrate of eosinophils, mast cells and lymphocytes. Relatively distinct features include the strong male predominance amongst adult patients, and the expression of the eosinophil chemokine eotaxin 3. Current first line treatments such as strict dietary modification and corticosteroids fail many patients. Looking forward, clarification of distinct genotype/phenotype associations, determining the reversibility of remodelling following treatment, and the development of new pharmacotherapies that target fibrotic pathways (as opposed to eosinophilic inflammation per se) or specifically improve barrier integrity appear relevant.

AB - Eosinophilic esophagitis (EoE) is considered to be a chronic antigen-driven disease whereby food and/or aeroallergens induce a chronic inflammatory infiltrate in the esophagus, resulting in pathological hyperplasia of the epithelia and muscular layers, and fibrosis of the lamina propria (referred to collectively as remodelling) and the symptoms of dysphagia and food impaction. EoE shares features with other atopic conditions of asthma and atopic dermatitis, such as a TH2 cytokine milieu and a mixed inflammatory infiltrate of eosinophils, mast cells and lymphocytes. Relatively distinct features include the strong male predominance amongst adult patients, and the expression of the eosinophil chemokine eotaxin 3. Current first line treatments such as strict dietary modification and corticosteroids fail many patients. Looking forward, clarification of distinct genotype/phenotype associations, determining the reversibility of remodelling following treatment, and the development of new pharmacotherapies that target fibrotic pathways (as opposed to eosinophilic inflammation per se) or specifically improve barrier integrity appear relevant.

KW - Allergy

KW - Diet

KW - Dysphagia

KW - Eosinophil

KW - Esophagitis

KW - Remodelling

UR - http://www.scopus.com/inward/record.url?scp=84921297863&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2014.09.001

DO - 10.1016/j.pharmthera.2014.09.001

M3 - Article

VL - 146

SP - 12

EP - 22

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -